Skip to main content
SpringerLink
Log in

Febuxostat vs allopurinol for gout: cardiovascular safety

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Gao L, et al. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clinical Cardiology : 20 May 2021. Available from: URL: http://doi.org/10.1002/clc.23643

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Febuxostat vs allopurinol for gout: cardiovascular safety. Reactions Weekly 1858, 9 (2021). https://doi.org/10.1007/s40278-021-96727-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-96727-4

Search

Navigation